Viral Vector GMP ReiThera is a Rome based CDMO delivering GMP manufacturing and process development for viral vectors, including AAV, LV, AdV, MVA and HSV. Its capability set covers scalable stirred-tank bioreactors from 50L to 2000L, fixed-bed bioreactors for adherent cell growth, plus a filling suite and quality control laboratories. This positions ReiThera as a strong partner for gene therapy and vaccine programs seeking European GMP manufacturing with end-to-end CDMO support from development through early clinical production.

EU Manufacturing Hub Located in Rome, ReiThera provides EU based manufacturing capacity with a GMP facility enabling nearshore options for European and international clients. The integrated HQ, R&D labs and manufacturing suite support technology development, clinical production and quality control at a single site, helping shorten time to clinic and reduce supply chain risk.

Strategic Partnerships ReiThera has a proven partnership track record with Trellis Research Group for an AAV manufacturing framework, a Master Service Agreement with SillaJen for the SJ-600 cancer virus platform, and collaboration with Sabin Vaccine Institute on a Phase 2 Sudan ebolavirus vaccine program. These partnerships demonstrate the companys ability to operate in co development, tech transfer and large scale manufacturing contexts.

LMIC Vaccine Focus In 2022 ReiThera and Exothera collaborated to develop large scale, low cost per dose vaccine manufacturing processes for low and middle income countries. This shows capability to deliver affordable production, technology transfer and capacity building for global health initiatives, aligning with bids for vaccine manufacturing programs in resource constrained markets.

Growth Momentum Leadership changes in 2024 with a new CEO and ongoing capacity expansion, alongside modest revenue and funding, signal a growth trajectory and openness to new long term CDMO partnerships. This momentum presents opportunities for process development, GMP manufacturing and fill finish collaborations with gene therapy, vaccines and viral vector programs.